Incidence, antimicrobial resistance and mortality of Klebsiella pneumoniae bacteraemia in Shanghai, China, 2018–2022

References

• Delle Rose D, Pezzotti P, Fontana C, et al. An in-depth analysis of nosocomial bloodstream infections due to gram-negative bacilli: clinical features, microbiological characteristics and predictors of mortality in a 1 year, prospective study in a large tertiary care Italian hospital. Infect Dis (Lond). 2019;51(1):12–22. doi: 10.1080/23744235.2018.1492149.
   PubMed Web of Science ®Google Scholar
• Pau CK, Ma FF, Ip M, et al. Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong. Infect Dis (Lond). 2015;47(5):283–288. doi: 10.3109/00365548.2014.985710.
   PubMed Web of Science ®Google Scholar
• Holmes CL, Anderson MT, Mobley HLT, et al. Pathogenesis of gram-negative bacteremia. Clin Microbiol Rev. 2021;34(2):e00234-20. doi: 10.1128/CMR.00234-20.
   PubMed Web of Science ®Google Scholar
• Chen J, Ma H, Huang X, et al. Risk factors and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary-care hospital in China: an eight-year retrospective study. Antimicrob Resist Infect Control. 2022;11(1):161. doi: 10.1186/s13756-022-01204-w.
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi: 10.1186/s12941-017-0191-3.
   PubMed Web of Science ®Google Scholar
• Quan J, Zhao D, Liu L, et al. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China. J Antimicrob Chemother. 2017;72(1):273–280. doi: 10.1093/jac/dkw372.
   PubMed Web of Science ®Google Scholar
• Wang Z, Du M, Cao H, et al. Epidemiology and risk factors of nosocomial infections in a Chinese tertiary-care hospital: a 10-year retrospective case-control study. Infect Dis (Lond). 2024;56(4):320–329. doi: 10.1080/23744235.2024.2310647.
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi: 10.1007/s10096-019-03673-1.
   PubMed Web of Science ®Google Scholar
• Dong N, Yang X, Chan E, et al. Klebsiella species: taxonomy, hypervirulence and multidrug resistance. EBioMedicine. 2022;79:103998. doi: 10.1016/j.ebiom.2022.103998.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Carnelutti A, et al. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749–761. doi: 10.1080/14787210.2018.1522249.
   PubMed Web of Science ®Google Scholar
• Lin Y-T, Siu LK, Lin J-C, et al. Seroepidemiology of Klebsiella pneumoniae colonizing the intestinal tract of healthy Chinese and overseas Chinese adults in Asian countries. BMC Microbiol. 2012;12(1):13. doi: 10.1186/1471-2180-12-13.
   PubMedGoogle Scholar
• Arena F, Menchinelli G, Di Pilato V, et al. Resistance and virulence features of hypermucoviscous Klebsiella pneumoniae from bloodstream infections: results of a nationwide Italian surveillance study. Front Microbiol. 2022;13:983294. doi: 10.3389/fmicb.2022.983294.
   PubMed Web of Science ®Google Scholar
• Pomakova DK, Hsiao C-B, Beanan JM, et al. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. Eur J Clin Microbiol Infect Dis. 2012;31(6):981–989. doi: 10.1007/s10096-011-1396-6.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao C, Wang Q, et al. High prevalence of hypervirulent Klebsiella pneumoniae infection in China: geographic distribution, clinical characteristics, and antimicrobial resistance. Antimicrob Agents Chemother. 2016;60(10):6115–6120. doi: 10.1128/AAC.01127-16.
   PubMed Web of Science ®Google Scholar
• Chang H, Wei J, Zhou W, et al. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: clinical impact of carbapenem resistance in a large tertiary hospital of China. J Infect Public Health. 2020;13(5):784–790. doi: 10.1016/j.jiph.2019.11.014.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Y, Liu P, et al. Risk factors and mortality for elderly patients with bloodstream infection of carbapenem resistance Klebsiella pneumoniae: a 10-year longitudinal study. BMC Geriatr. 2022;22(1):573. doi: 10.1186/s12877-022-03275-1.
   PubMed Web of Science ®Google Scholar
• Song F, Zhang K, Huang J, et al. Clinical characteristics, risk factors, and outcomes of patients with polymicrobial Klebsiella pneumoniae bloodstream infections. Biomed Res Int. 2021;2021:6619911–6619910. doi: 10.1155/2021/6619911.
   PubMed Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi: 10.1016/j.ajic.2008.03.002.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x.
   PubMed Web of Science ®Google Scholar
• Liu KS, Tong YS, Lee MT, et al. Risk factors of 30-day all-cause mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. J Pers Med. 2021;11(7):616. doi: 10.3390/jpm11070616.
   PubMed Web of Science ®Google Scholar
• Chumbita M, Puerta-Alcalde P, Gudiol C, et al. Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock. Antimicrob Agents Chemother. 2022;66(2):e0174421. doi: 10.1128/AAC.01744-21.
   PubMed Web of Science ®Google Scholar
• Xiao T, Zhu Y, Zhang S, et al. A retrospective analysis of risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in nontransplant patients. J Infect Dis. 2020;221(Suppl 2):S174–S183. doi: 10.1093/infdis/jiz559.
   PubMed Web of Science ®Google Scholar
• Humphries R, Bobenchik AM, Hindler JA, et al. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol. 2021;59(12):e0021321. doi: 10.1128/JCM.00213-21.
   PubMed Web of Science ®Google Scholar
• Giske CG, Turnidge J, Cantón R, et al. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2022;60(3):e0027621. doi: 10.1128/JCM.00276-21.
   PubMed Web of Science ®Google Scholar
• Valik JK, Hedberg P, Holmberg F, et al. Impact of the COVID-19 pandemic on the incidence and mortality of hospital-onset bloodstream infection: a cohort study. BMJ Qual Saf. 2022;31(5):379–382. doi: 10.1136/bmjqs-2021-014243.
   PubMed Web of Science ®Google Scholar
• Namikawa H, Niki M, Niki M, et al. Clinical and virulence factors related to the 30-day mortality of Klebsiella pneumoniae bacteremia at a tertiary hospital: a case-control study. Eur J Clin Microbiol Infect Dis. 2019;38(12):2291–2297. doi: 10.1007/s10096-019-03676-y.
   PubMed Web of Science ®Google Scholar
• Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83(4):307–313. doi: 10.1016/j.jhin.2012.10.012.
   PubMed Web of Science ®Google Scholar
• Cao Z, Yue C, Kong Q, et al. Risk factors for a hospital-acquired carbapenem-resistant Klebsiella pneumoniae bloodstream infection: a five-year retrospective study. Infect Drug Resist. 2022;15:641–654. doi: 10.2147/IDR.S342103.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Montalti R, Castelli P, et al. Carbapenem-resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect Dis. 2016;16(1):538. doi: 10.1186/s12879-016-1876-5.
   PubMedGoogle Scholar
• Tian L, Tan R, Chen Y, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control. 2016;5(1):48. doi: 10.1186/s13756-016-0145-0.
   PubMedGoogle Scholar
• Babich T, Naucler P, Valik JK, et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. Int J Antimicrob Agents. 2020;55(2):105847. doi: 10.1016/j.ijantimicag.2019.11.004.
   PubMed Web of Science ®Google Scholar
• Kim YA, Lee SJ, Park YS, et al. Risk factors for carbapenemase-producing enterobacterales infection or colonization in a korean intensive care unit: a case-control study. Antibiotics (Basel). 2020;9(10):680. doi: 10.3390/antibiotics9100680.
   PubMed Web of Science ®Google Scholar
• Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–597. doi: 10.1016/j.ijantimicag.2016.09.010.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi: 10.1093/cid/cis588.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu H, Huang H, et al. Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):161. doi: 10.1186/s12879-024-09024-6.
   PubMed Web of Science ®Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–2309. doi: 10.1093/jac/dku168.
   PubMed Web of Science ®Google Scholar
• Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection. 2013;41(1):61–67. doi: 10.1007/s15010-012-0354-2.
   PubMed Web of Science ®Google Scholar
• Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9(1):79. doi: 10.1186/s13756-020-00728-3.
   PubMed Web of Science ®Google Scholar
• Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54–60. doi: 10.1111/j.1469-0691.2011.03478.x.
   PubMed Web of Science ®Google Scholar
• Cohen MJ, Anshelevich O, Raveh D, et al. Acquisition of multidrug-resistant organisms among hospital patients hospitalized in beds adjacent to critically ill patients. Infect Control Hosp Epidemiol. 2006;27(7):675–681. doi: 10.1086/505919.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Perencevich EN. Addressing the emergence and impact of multidrug-resistant gram-negative organisms: a critical focus for the next decade. Infect Control Hosp Epidemiol. 2014;35(4):333–335. doi: 10.1086/675592.
   PubMed Web of Science ®Google Scholar
• Thaden JT, Li Y, Ruffin F, et al. Increased costs associated with bloodstream infections caused by multidrug-resistant gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother. 2017;61(3):e01709-16. doi: 10.1128/AAC.01709-16.
   PubMed Web of Science ®Google Scholar